Abstract
The previous decade has witnessed remarkable advances in our understanding and treatment of chronic lymphocytic leukemia. Chemoimmunotherapy has provided patients with unprecedented remission rates and has improved survival compared to chemotherapy alone. However, the availability of targeted therapies and monoclonal antibodies argues for exploring non-cytotoxic and biologic regimens for this disease. In this article, we review available targeted and non-chemotherapeutic agents for CLL, attempting to position these therapies in the treatment paradigm of CLL in the era of risk stratification as we move forward.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 374-386 |
| Number of pages | 13 |
| Journal | Leukemia and Lymphoma |
| Volume | 52 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2011 |
Fingerprint
Keywords
- chemotherapeutic approaches
- Immunotherapeutic approaches
- lymphoid leukemia
- pharmacotherapeutics
- signaling therapies
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
Biologic agent activity in chronic lymphocytic leukemia : A framework for future therapies. / Nabhan, Chadi; Dalal, Neil; Mehta, Jayesh; Kay, Neil Elliot.
In: Leukemia and Lymphoma, Vol. 52, No. 3, 03.2011, p. 374-386.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Biologic agent activity in chronic lymphocytic leukemia
T2 - A framework for future therapies
AU - Nabhan, Chadi
AU - Dalal, Neil
AU - Mehta, Jayesh
AU - Kay, Neil Elliot
PY - 2011/3
Y1 - 2011/3
N2 - The previous decade has witnessed remarkable advances in our understanding and treatment of chronic lymphocytic leukemia. Chemoimmunotherapy has provided patients with unprecedented remission rates and has improved survival compared to chemotherapy alone. However, the availability of targeted therapies and monoclonal antibodies argues for exploring non-cytotoxic and biologic regimens for this disease. In this article, we review available targeted and non-chemotherapeutic agents for CLL, attempting to position these therapies in the treatment paradigm of CLL in the era of risk stratification as we move forward.
AB - The previous decade has witnessed remarkable advances in our understanding and treatment of chronic lymphocytic leukemia. Chemoimmunotherapy has provided patients with unprecedented remission rates and has improved survival compared to chemotherapy alone. However, the availability of targeted therapies and monoclonal antibodies argues for exploring non-cytotoxic and biologic regimens for this disease. In this article, we review available targeted and non-chemotherapeutic agents for CLL, attempting to position these therapies in the treatment paradigm of CLL in the era of risk stratification as we move forward.
KW - chemotherapeutic approaches
KW - Immunotherapeutic approaches
KW - lymphoid leukemia
KW - pharmacotherapeutics
KW - signaling therapies
UR - http://www.scopus.com/inward/record.url?scp=79951705088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951705088&partnerID=8YFLogxK
U2 - 10.3109/10428194.2010.545461
DO - 10.3109/10428194.2010.545461
M3 - Article
C2 - 21323519
AN - SCOPUS:79951705088
VL - 52
SP - 374
EP - 386
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 3
ER -